# A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

> **NCT00042666** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 55 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** LY317615

## Key facts

- **NCT ID:** NCT00042666
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042666, "A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00042666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*